RE:RE:RE:RE:SA REPORTS FOURTH Q RESULTSWell I did listen to the RVX webcast and my initial reaction is what I predicted. It was very much a rehash of slides from the past and "and we are excited about that" comments by Don.
He played up that rvx-208 has been dosed on over 1000 patients and still has a high safety profile but he did not explain exactly who these 1000+ are...e.g. SUSTAIN, ASSURE, previous trials, BETonMACE, etc?
He talked about funding but other than saying funding will get done (which I believe) there was absolutely nothing concrete.
I sense BETonMACE is falling behind but there are trials that will start in Taiwan and Russia and will be funded by Hepalink and the Russian partner respectively. That is good.
On the slide where Don talked about Ray Krocs book and the time it took various companies to reach $1,000,000,000 in revenue he seemed to imply RVX would be there in 2021?????? This sure erodes credibility for me given how non committal his presentation was. Perhaps I did not understand what he was saying. Perhaps it was the quality of the air and Pacific Ocean in Hawaii that caused this hallucination?
He tended to emphasize how advanced RVX is on their BET inhibitor platform. Perhaps, but why isn't a suitor jumping in?
Licensing deals including compounds and regional deals were discussed with nothing concrete.
I was reluctant to post tonight because I really want to read posts from those that attended the meetings. Perhaps as others digest what happened today and post I will change my mind.
I see this as another of Don's "skating away on the thin ice of a new day". He pulled it off, got off easy and will once again collect another $800,000 pay cheque next year while the science carries on.
As I posted previously I truly hoped to be proven wrong but unfortunately I was dead right. I'm very disappointed.
I will read other posts tomorrow and hope that new perspectives will make me more positive.
GLTA
Toinv